COMMUNIQUÉS West-GlobeNewswire

OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipients
09/09/2026
Nantes, France, September 9, 2026 – 6pm CEST – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the “Company”) welcomes the announcement by its licensee Veloxis Pharmaceuticals, Inc. that the first patient [...]
OSE Immunotherapeutics se félicite de l’inclusion du premier patient traité par Veloxis dans l’étude de phase 2 RENGEVITY-201 évaluant le pegrizeprument (VEL-101) dans la prévention du rejet d’organe chez les patients transplantés rénaux
09/09/2026
Nantes, le 9 septembre 2026 – 18h00 CEST – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnémo : OSE) (la « Société ») se félicite de l’annonce de son partenaire Veloxis Pharmaceuticals, Inc. relative au traitement [...]
Fast Company Names Visory Health to Its 2026 Best Workplaces for Innovators List
09/09/2026
The company’s collaborative culture and commitment to empowering employees earned the prestigious recognition ESTERO, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Visory Health , a top-three prescription discount card [...]
Quetzal Therapeutics Appoints Harindra R. Abeysinghe, Ph.D., as Chief Regulatory and Quality Officer
09/09/2026
CHICAGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare diseases, including hematologic malignancies, today announced the appointment of [...]
Wellcome Leap Appoints John Young and Thomas Glanzmann to Board of Directors
09/09/2026
SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Wellcome Leap (Leap), a U.S. nonprofit founded by the Wellcome Trust to accelerate breakthroughs in human health, today announced that John Young and Thomas Glanzmann have [...]
Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference
09/09/2026
Press release – No. 15 / 2026 Zealand Pharma to participate in the Morgan Stanley 24 th Annual Global Healthcare Conference Copenhagen, Denmark, September 9, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), [...]
EssilorLuxottica: EssilorLuxottica Board of Directors unanimously reaffirms confidence in the Company’s leadership and strategy
09/09/2026
EssilorLuxottica Board of Directors unanimously reaffirms confidence in the Company’s leadership and strategy Paris, France (9 September 2026) – With reference to recent press reports and public statements, the [...]
EssilorLuxottica: Le Conseil d’administration d’EssilorLuxottica réaffirme à l’unanimité sa confiance dans le management et la stratégie de l’entreprise
09/09/2026
Le Conseil d’administration d’EssilorLuxottica réaffirme à l’unanimité sa confiance dans le management et la stratégie de l’entreprise Paris, France (9 septembre 2026) – Faisant suite aux récentes informations parues [...]
LifeStance Health Group Announces Pricing of Secondary Public Offering
09/09/2026
SCOTTSDALE, Ariz., Sept. 09, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health [...]
Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum
09/09/2026
SARASOTA, FLA., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), ”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a [...]
A Syngenta e a Amoéba concluíram um acordo de distribuição exclusivo na Europa para oferecer aos produtores de cereais uma inovação biofungicida
09/09/2026
Bâle (Suíça) e Chassieu (França), Sept. 09, 2026 (GLOBE NEWSWIRE) -- Este acordo exclusivo abrangerá o mercado de cereais na União Europeia, no Reino Unido, na Ucrânia e na Suíça, com os primeiros lançamentos comerciais [...]
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
09/09/2026
Company continues to advance Phase 2 DURIPANC study and broader clinical strategy evaluating Ampligen’s potential to reshape the tumor microenvironment and enhance checkpoint inhibition Access it here OCALA, Fla., Sept [...]
John Patrick University Launches New Radiography Bridge Program to Help Address Growing Demand for Radiologic Technologists
09/09/2026
New pathway allows qualified Limited Scope Radiographers to apply up to 21 credits toward an Associate of Science degree and potentially complete the program in as little as 16 months SOUTH BEND, Ind., Sept. 09, 2026 ( [...]
Independent Model Estimates Up To $11,142 in Gross Medical Cost Savings Per Member Over Five Years for Omada’s GLP-1 Program
09/09/2026
New model demonstrates the clinical and economic value of medication persistence, companion program engagement, and projected disease risk reduction SAN FRANCISCO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq [...]
Parity and Maine RMOMS Partnership Demonstrates New Approach to Strengthening Rural Maternity Care
09/09/2026
Work across three Maine hospitals identifies more than $1.1 million in potential annual nurse labor savings while supporting safe, patient-centered staffing and long-term maternity care sustainability PORTLAND, Maine, [...]
H1 Acquires Defacto Health to Strengthen Provider Network Intelligence
09/09/2026
Acquisition brings provider-network data and experienced healthcare data leaders to H1 NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- H1 , the AI-powered platform that connects the world to the right doctors, today [...]
Traver Strategic Holdings Acquires Apprio and Launches Varetis, Inc.
09/09/2026
ATLANTA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Traver Strategic Holdings LLC today announced its acquisition of Apprio, Inc., and the launch of Varetis, Inc., which will build on Apprio’s decades of federal experience [...]
Editas Medicine Reports Inducement Grants to New Chief Medical Officer
09/09/2026
CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an [...]
ImPact Biotech Announces Completion of Treatment in Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC and Positive Regulatory Updates
09/09/2026
– Successful t reatment of 91 patients with consistent safety and efficacy results observed to date ; interim data to be presented at ESMO Congress in October 2026 – – W ritten feedback from FDA following pre-NDA [...]

Pages